Stockreport

Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatme [Read more]